Guangzhou Baiyunshan Hanfang Launches Certified Medicinal Soybean Oil for Global Procurement

China’s Specialty Pharma Leader Delivers GMP-Compliant Injectable Grade Raw Material to Secure Supply Chains

Guangzhou, China – 2026 – Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd., a leading provider of high-end pharmaceutical lipid excipients and specialty APIs, today announced the global availability of its injectable medicinal soybean oil. This domestically developed product addresses the critical pain point of unstable supply for global pharmaceutical manufacturers, offering a reliable, cost-effective alternative to imported equivalents. With core advantages including green production technology, international regulatory compliance, and scalable capacity, the launch aims to strengthen global pharmaceutical supply chains and expand the company’s footprint in the global specialty raw material market. Orders are now open worldwide through official channels and authorized distributors.

Core Technological Breakthroughs & Product Advantages

1. Domestic Supply Security: The injectable medicinal soybean oil breaks long-term foreign monopoly in high-end pharmaceutical lipid excipients, supporting a jump in localization rate from 10% to 90% for related materials. It serves as a reliable energy supplement and excipient for high-end injectable drug production, eliminating supply chain risks for global pharma clients.
2. Green Production Technology: The product is manufactured using the company’s proprietary integrated green technology, combining supercritical CO₂ extraction, membrane separation, and chromatographic separation to replace traditional polluting processes, ensuring environmental sustainability and product purity.
3. Proven Performance: As a key component in injectable emulsions and lipid-based formulations, the soybean oil meets strict quality standards, providing consistent performance to support drug stability and efficacy.

Global Compliance & Certifications

To meet global market access requirements, the injectable medicinal soybean oil has obtained multiple international certifications, including EU CEP, US FDA US-DMF, Mexico Cofepris, and India DCGI. The company also holds national-level qualifications such as National Specialized, Sophisticated, Unique, and New "Little Giant" Enterprise (2024), National Green Factory, and operates the only national engineering research center for traditional Chinese medicine process technology and new drug development, further reinforcing its authority in the sector.

Availability & Customization Services

The injectable medicinal soybean oil is now available for global orders via the official website (http://byshanhanfang.com/) and the company’s global distribution network covering over 20 countries and regions. Beyond standard products, Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. offers customized processing services tailored to specific formulation requirements of pharmaceutical and medical food manufacturers, ensuring flexible solutions for diverse client needs.

Executive Quote

"The launch of our injectable medicinal soybean oil marks a key step in our global strategy to address 'bottleneck' technologies and secure pharmaceutical supply chains," said Xu Wendong, General Manager and Deputy Director of the National Engineering Research Center at Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. "We are committed to providing global clients with domestically developed, high-quality raw materials that meet international standards, supporting their production efficiency and supply chain resilience."

Industry Context & Strategic Alignment

Against the backdrop of growing global demand for reliable pharmaceutical raw materials, foreign monopolies have long posed risks to supply chain stability. Guangzhou Baiyunshan Hanfang’s breakthrough in domestic production of high-end lipid excipients aligns with the global trend of supply chain localization, offering a trusted alternative for manufacturers worldwide. The company’s track record of serving leading global clients including B. Braun, AstraZeneca, and Kelun Pharma further validates its product quality and reliability.

Future Plans

Looking ahead, Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. will continue to invest in R&D for high-end pharmaceutical lipid technologies, expanding its product portfolio to meet evolving global market needs. The company aims to achieve double-digit growth in revenue and profit in 2026, while enhancing its global sales and service network to provide localized support for clients in more regions.

About Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd.

Founded in 1998, Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. is a state-owned holding enterprise under the Guangzhou Pharmaceutical Holdings (GPHL) Group, specializing in high-end pharmaceutical lipid excipients, specialty APIs, health products, and technical services. With over 240 patents, a national-level engineering research center, and a team of 11 PhDs and national-level experts, the company serves more than 1,000 clients across 20+ countries. Its mission is to achieve technological self-reliance, break "bottleneck" technologies, and safeguard global pharmaceutical supply chains.

Contact Information

Company: Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd.
Official Website: http://byshanhanfang.com/

© 2026 Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. All rights reserved.